Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg

Sunday, December 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the results of long-term dosing with ALG-000184 in subjects positive for HBeAg, highlighting unprecedented reductions in HBV markers, including HBsAg. These findings suggest a significant advancement in the treatment of chronic HBV infection, potentially improving patient outcomes. The results may pave the way for further research and development in this area.
Price reaction · baseline $17.5275 (2023-12-01 close) · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Unprecedented multi-log reductions in HBV markers observed.
  • Long-term dosing shows promising results in HBeAg positive subjects.
  • Potential for significant impact on chronic HBV infection management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a treatment being studied for chronic HBV infection.

What were the results of the dosing study?

The study showed unprecedented multi-log reductions in HBV markers.

Who were the subjects in the study?

The subjects were HBeAg positive individuals with chronic HBV infection.

What is the significance of HBsAg reduction?

Reduction in HBsAg is crucial for improving patient outcomes in HBV treatment.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 HBV chronic HBV infection HBeAg positive HBsAg
Last updated: Dec 3, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →